Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Expectations for Bristol Myers Squibb's Q3 results have significantly declined. Despite this, check out why I maintain a "Buy ...

Equities researchers at Leerink Partnrs decreased their Q3 2024 EPS estimates for Bristol-Myers Squibb in a research report ...

Fintel reports that on October 25, 2024, Citigroup downgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Buy to ...

Shares of Bristol Myers Squibb Co. BMY advanced 1.23% to $52.76 Tuesday, on what proved to be an all-around poor trading ...

Bristol Myers Squibb and Ideaya Biosciences both released detailed snapshots of early-stage data for cancer drugs targeting ...

Citi analyst Geoff Meacham downgraded Bristol Myers (BMY) to Neutral from Buy with a price target of $55, down from $75, following a transfer ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market ...

Bristol-Myers Squibb (BMY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from Leerink Partners maintained a Hold rating on ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $52.76 which represents a slight increase of $0.64 or 1.23% from the prior close of $52.12. The stock opened at ...

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...